<DOC>
	<DOCNO>NCT01978587</DOCNO>
	<brief_summary>The purpose study evaluate effect hemodialysis pharmacokinetics ( PK ) JTZ-951 evaluate safety 2 dose JTZ-951 subject end-stage renal disease ( ESRD ) receive hemodialysis</brief_summary>
	<brief_title>Effect Hemodialysis PK JTZ-951 Subjects With End-stage Renal Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Subjects ESRD receive maintenance hemodialysis least 12 week prior Screening Visit Body weight ( postdialysis weight ) great 45.0 kg body mass index 20.0 40.0 kg/m2 ( inclusive ) Screening Visit Acute coronary syndrome ( e.g. , myocardial infarction ) within 1 year prior admission Uncontrolled hypertension Screening Visit Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>End-stage Renal Disease</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>